Up 62%: A Stock-Friendly Hostile Bid

Gentiva Health  shareholders jumped 62% today after Kindred Healthcare made public a $533 million bid for the company that had been rejected by Gentiva's management. Kindred has offered to take the deal from half-and-half cash and stock to all cash to make the deal more attractive, and Kindred also intends to assume Gentiva's debt, which spikes the deal's price to $1.6 billion.

M&A transactions to achieve better scale have been all the rage in health care, and this is no different -- Gentiva offers Kindred a nice opportunity to strengthen its home health and hospice business, and the combined entity would be the largest by revenue in the post-acute care market.

In the video below, from Thursday's Market Checkup, Motley Fool health care analysts Michael Douglass and David Williamson discuss the deal and what it could mean for both companies.

Even after Gentiva's run today, it may struggle to keep up with this top stock
Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article Up 62%: A Stock-Friendly Hostile Bid originally appeared on Fool.com.

David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story